Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 200

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 200
---
 litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. 126

Principal shareholders The following table sets forth information regarding the beneficial ownership of our ordinary shares as of the date of this prospectus, and as adjusted to reflect the sale of our ordinary shares included in the units offered by this prospectus, and assuming no purchase of units in this offering, by: •each person known by us to be the beneficial owner of more than 5% of our issued and outstanding ordinary shares; •each of our directors and officers; and •all our directors and officers as a group. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all of our ordinary shares beneficially owned by them. The following table does not reflect record or beneficial ownership of the rights included in the units offered by this prospectus or the private rights. The post -offeringownership percentage column below assumes that the underwriters do not exercise their over -allotmentoption, that our initial shareholders surrender and forfeit 1,285,714 founder shares, and that there are 29,171,429 ordinary shares issued and outstanding after this offering.

|                                                                                |     | Before Offering |     |                 |   |     | After Offering |     |                 |   |
| Name and Address of Beneficial Owner(1)                                        |     |       Number of 
          Shares 
    Beneficially 
           Owned |     |     Approximate 
   Percentage of 
     Outstanding 
 Ordinary Shares |   |     |      Number of 
         Shares 
   Beneficially 
          Owned |     |     Approximate 
   Percentage of 
     Outstanding 
 Ordinary Shares |   |
| Drugs Made In America Acquisition LLC(2)(3)                                    |     |       9,857,143 |     |             100 | % |     |